 
       
      | Current issue
			Archive
		
				Videos
				Articles in press
				About the journal
				Supplements
					Editorial board
				Reviewers
				Abstracting and indexing
		
			
	
					Subscription
				Contact
				Instructions for authors
	             Publication charge
     			Ethical standards and procedures Editorial System Submit your Manuscript | 
           1/2025
	 vol. 127 abstract: Case report Zoledronate-induced orbital and ocular inflammation
                       
                    Julia  Dyrda
                 
                       1
                     , 
                    Karolina  Starkowska
                 
                       1
                     
 KLINIKA OCZNA 2025, 127, 1: 34-36 Online publish date: 2025/03/25 
      View
         full text
       
	
	Get citation
 ENWEndNote BIBJabRef, Mendeley RISPapers, Reference Manager, RefWorks, Zotero AMA APA Chicago Harvard MLA Vancouver 
    Orbital inflammation is one of numerous adverse effects of bisphosphonates. The symptoms include palpebral oedema, conjunctival chemosis, ocular motility impairment, proptosis and decreased visual acuity. This condition may coincide with other ocular adverse effects, as presented in this case report of a patient who developed orbital inflammation along with scleritis and uveitis after the administration of zoledronic acid for bone metastases of prostate cancer. He was admitted to the hospital with severely decreased visual acuity (hand motion) and massive oedema and proptosis. Following the execution of diagnostic imaging, intravenous steroids (methylprednisolone 0.5 g for 3 days) were introduced, leading to rapid alleviation of symptoms. At discharge the patient presented full recovery of visual acuity, which is typical for bisphosphonate ocular adverse effects treated with steroids.
     keywords: orbital inflammation, bisphosphonates, zoledronic acid, zoledronate, adverse event |